cyclophosphamide is an anti-cancer medication produced by Eugia Pharma Speclts. This drug contains the active ingredient, cyclophosphamide, and was first authorized for market use on August 25, 2021. Currently, cyclophosphamide holds a total of 1 patent, with none being expired so far.
Cyclophosphamide generic version would be possible for production post June 26, 2035, which is when the last active patent owned by Eugia Pharma Speclts on Cyclophosphamide expires. This implies that other manufacturers could potentially begin producing generic versions of Cyclophosphamide after this date, making the medication more accessible to patients.
cyclophosphamide is an effective medication for treating various types of cancer. It works by slowing or stopping the growth of cancer cells. The active ingredient in cyclophosphamide, also named cyclophosphamide, interferes with the growth of DNA and RNA of the cancer cells by substituting their building blocks, causing these cells to die and thus inhibiting cancer development.
The sole patent of Cyclophosphamide, US9662342 titled 'Formulations of cyclophosphamide liquid concentrate', is currently active and is set to expire on June 26, 2035. The availability of Cyclophosphamide generic versions would be possible post this date. Further details of the patent are provided below: